Mantripragada Kalyan C, Safran Howard
The Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI 02903, USA.
Future Oncol. 2016 May;12(9):1125-33. doi: 10.2217/fon-2015-0006. Epub 2016 Mar 4.
The two combination chemotherapy regimens FOLFIRINOX and gemcitabine plus nab-paclitaxel represent major breakthroughs in the management of metastatic pancreatic cancer. Both regimens showed unprecedented survival advantage in the setting of front-line therapy. However, their application for treatment of patients in the community is challenging because of significant toxicities, thus limiting potential benefits to a narrow population of patients. Modifications to the dose intensity or schedule of those regimens improve their tolerability, while likely retaining survival advantage over single-agent chemotherapy. Newer strategies to optimize these two active regimens in advanced pancreatic cancer are being explored that can help personalize treatment to individual patients.
两种联合化疗方案FOLFIRINOX以及吉西他滨联合纳米白蛋白结合型紫杉醇代表了转移性胰腺癌治疗方面的重大突破。在一线治疗中，这两种方案均显示出前所未有的生存优势。然而，由于其显著的毒性，它们在社区患者治疗中的应用具有挑战性，从而将潜在益处局限于一小部分患者。对这些方案的剂量强度或给药方案进行调整可提高其耐受性，同时可能保持相对于单药化疗的生存优势。目前正在探索优化这两种晚期胰腺癌有效方案的新策略，以帮助为个体患者制定个性化治疗方案。
